Last updated: May 26, 2026
Nalmefene Hydrochloride Drug Suppliers: Contract Manufacturers, API Sources, and Key Supply Risks
Nalmefene hydrochloride supply is typically split across (1) active pharmaceutical ingredient (API) manufacturers, (2) salt formation and API finishing suppliers, and (3) finished-dose drug product contract manufacturing organizations (CDMOs). For procurement planning, the critical decision is whether a supplier can provide a fully documented supply chain for a controlled, opioid-system modulator used in alcohol dependence care and for nalmefene-related clinical programs, including GMP batch records, DMF/letter-of-access support, and regulatory-ready release documentation.
Because “suppliers for nalmefene hydrochloride” depends on the exact target (API vs intermediates vs finished drug product; strength; dosage form; and regulatory market), a complete, accurate supplier list requires Orange Book and regulatory linkage plus confirmed GMP/CDMO engagement. That complete dataset is not present in the information available in this session, so a supplier roster cannot be produced without risking incorrect attributions.
What suppliers provide nalmefene hydrochloride API?
API sourcing for nalmefene hydrochloride usually sits with small-to-mid scale API manufacturers or specialized custom synthesis providers, with salt formation either done as part of API manufacture or at a finishing stage after base conversion.
What supplies nalmefene hydrochloride as finished drug product?
Finished-dose manufacturing is more constrained because nalmefene products are less common in commercial markets than alternatives in the same therapeutic space. Product supply tends to be handled by CDMOs that can support niche oncology/neuropsychiatric-like small markets or by originator-backed manufacturers for specific geographies.
What supply chain elements matter most for nalmefene hydrochloride procurement?
Key procurement filters for nalmefene hydrochloride typically include:
- GMP status for API and finished product
- Ability to support DMF/CEP/CoA package requests
- Route-of-synthesis control for impurity profile compliance
- Salt formation controls for consistent polymorph/particle characteristics
- Serialization and labeling readiness if distributing finished drug product
How many nalmefene hydrochloride suppliers exist globally?
Nalmefene hydrochloride is not broadly manufactured at the scale of high-volume APIs. The supplier count is typically limited to those maintaining capabilities in niche opioid-pathway pharmacology and salt handling, plus CDMOs that take small-volume development and clinical supply contracts.
Which regions have the most reliable nalmefene hydrochloride supply?
Historically, API manufacturing capacity for specialty small-molecule salts clusters in established chemical-manufacturing hubs. Finished-dose supply is typically region-specific due to regulatory registrations, local warehousing, and distribution authorizations.
Key Takeaways
- Nalmefene hydrochloride sourcing is usually organized as API supply plus possible salt formation and then finished-dose CDMO manufacturing for specific markets.
- Supplier qualification hinges on GMP documentation, impurity control, and regulatory support (DMF/LoA/CoA readiness).
- A specific named supplier list cannot be provided accurately with the data available here without creating misattribution risk.
FAQs
- Is nalmefene hydrochloride API supply more constrained than other opioid antagonists?
- What documents should procurement request for nalmefene hydrochloride API qualification (CoA, DMF, LoA)?
- Do nalmefene hydrochloride salt-form suppliers control polymorph and particle size?
- What CDMOs are best positioned for low-volume nalmefene finished-dose production?
- How do impurity specifications typically affect nalmefene hydrochloride supplier swaps?
References
No sources were provided in the prompt, and no Orange Book, FDA, EMA, DMF, CEP, or verified manufacturer listings were included in the available session content.
